KDNY Chinook Therapeutics, Inc. Stock Quote

KDNY [NASD]

Index	-	P/E	-	EPS (ttm)	-6.20	Insider Own	0.20%	Shs Outstand	42.38M	Perf Week	7.29%
Market Cap	653.81M	Forward P/E	-	EPS next Y	-2.54	Insider Trans	14.64%	Shs Float	18.08M	Perf Month	-10.82%
Income	-81.60M	PEG	-	EPS next Q	-0.61	Inst Own	75.00%	Short Float	5.01%	Perf Quarter	0.82%
Sales	0.80M	P/S	817.26	EPS this Y	75.70%	Inst Trans	349.30%	Short Ratio	7.31	Perf Half Y	-7.99%
Book/sh	25.41	P/B	0.63	EPS next Y	2.70%	ROA	-26.60%	Target Price	-	Perf Year	-1.24%
Cash/sh	6.02	P/C	2.64	EPS next 5Y	9.00%	ROE	-68.70%	52W Range	10.50 - 21.68	Perf YTD	0.25%
Dividend	-	P/FCF	-	EPS past 5Y	-7.20%	ROI	-16.20%	52W High	-26.66%	Beta	0.06
Dividend %	-	Quick Ratio	11.10	Sales past 5Y	-59.20%	Gross Margin	-	52W Low	51.43%	ATR	1.12
Employees	96	Current Ratio	11.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	50.97	Volatility	6.68% 7.68%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	75.70%	Profit Margin	-	Rel Volume	0.91	Prev Close	15.24
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Apr 07 AMC	Payout	-	Avg Volume	123.71K	Price	15.90
Recom	1.50	SMA20	-0.52%	SMA50	-2.60%	SMA200	6.87%	Volume	112,394	Change	4.33%

Jan-06-21

Initiated

Wedbush

Outperform

$28

Dec-10-20

Initiated

Cantor Fitzgerald

Overweight

$31

Nov-16-20

Initiated

H.C. Wainwright

Buy

$28

Nov-02-20

Initiated

Evercore ISI

Outperform

$32

Oct-20-20

Upgrade

Oppenheimer

Perform → Outperform

$25

Apr-15-21 08:15AM	Chinook Therapeutics Presents Data During the ISN World Congress of Nephrology 2021 GlobeNewswire +10.43%
Apr-08-21 04:30PM	Chinook Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Apr-07-21 04:05PM	Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
08:15AM	Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases GlobeNewswire
Apr-05-21 08:15AM	Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger GlobeNewswire
Apr-01-21 04:15PM	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-30-21 04:26PM	Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress GlobeNewswire +6.96%
Mar-16-21 08:15AM	Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy GlobeNewswire -7.20%
Mar-02-21 04:15PM	Chinook Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Mar-01-21 08:15AM	Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases GlobeNewswire
Feb-23-21 08:15AM	Chinook Therapeutics to Present at 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit GlobeNewswire
Feb-17-21 04:15PM	Chinook Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire +5.34%
Feb-02-21 08:15AM	Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for CHK-336 for Treatment of Primary Hyperoxaluria GlobeNewswire
Jan-07-21 03:01AM	Who Has Been Buying Chinook Therapeutics, Inc. (NASDAQ:KDNY) Shares? Simply Wall St.
Jan-04-21 08:15AM	Chinook Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Dec-08-20 08:15AM	Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities GlobeNewswire
Nov-30-20 04:15PM	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-18-20 04:15PM	Chinook Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Nov-10-20 08:15AM	Chinook Therapeutics Announces Appointment of Eric Bjerkholt as Chief Financial Officer GlobeNewswire
Nov-05-20 05:07PM	Chinook Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Oct-22-20 11:15AM	Chinook Therapeutics Presents Data Across Kidney Disease Pipeline During the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined GlobeNewswire
Oct-09-20 12:45PM	Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined GlobeNewswire

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DOBMEIER ERIC	President, CEO	Dec 21	Option Exercise	0.35	20,000	7,000	76,837	Dec 22 07:47 PM
DOBMEIER ERIC	President, CEO	Dec 09	Buy	13.07	2,000	26,150	56,837	Dec 10 05:38 PM
DOBMEIER ERIC	President, CEO	Dec 08	Buy	13.24	2,000	26,483	54,837	Dec 10 05:38 PM
DOBMEIER ERIC	President, CEO	Nov 23	Buy	13.67	929	12,699	52,837	Nov 23 07:26 PM
DOBMEIER ERIC	President, CEO	Nov 20	Buy	13.69	571	7,817	51,908	Nov 23 07:26 PM
DOBMEIER ERIC	President, CEO	Nov 19	Buy	13.50	500	6,750	51,337	Nov 23 07:26 PM
DOBMEIER ERIC	President, CEO	Nov 11	Buy	13.75	2,500	34,375	50,837	Nov 13 06:13 PM
DOBMEIER ERIC	President, CEO	Nov 10	Buy	13.86	2,000	27,720	48,337	Nov 13 06:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience